Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and sequential administration with lipilimumab may impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Wada, Naoko, Irie, Hiroyuki, Hidaka, Takanori, Hashimoto, Akira, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252386/
https://www.ncbi.nlm.nih.gov/pubmed/30510916
http://dx.doi.org/10.3389/fonc.2018.00530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252386/
https://www.ncbi.nlm.nih.gov/pubmed/30510916
http://dx.doi.org/10.3389/fonc.2018.00530

Ejemplares similares